1. Academic Validation
  2. Virucidal effect of povidone-iodine against SARS-CoV-2 in vitro

Virucidal effect of povidone-iodine against SARS-CoV-2 in vitro

  • J Int Med Res. 2021 Dec;49(12):3000605211063695. doi: 10.1177/03000605211063695.
Ying Wang 1 Yutong Wu 2 Qingjing Wang 2 Jiajie Zhu 2 Wen Shi 3 Zetao Han 2 Yanjun Zhang 3 Keda Chen 2
Affiliations

Affiliations

  • 1 Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Centre for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Centre of Zhejiang University, Hangzhou, Zhejiang Province, China.
  • 2 Department of Basic Medical Sciences, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang Province, China.
  • 3 Department of Microbiology, Zhejiang Provincial Centre for Disease Control and Prevention, Hangzhou, Zhejiang Province, China.
Abstract

Objective: To evaluate the Antiviral activity of the oral disinfectant povidone-iodine (PVP-I) against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV2) in vitro.

Methods: The cytotoxic effects of PVP-I were determined in Vero and Calu-3 cell lines using that by Cell Counting Kit-8 assay. Viral load in the Cell Culture medium above infected cells was quantitated using real-time polymerase chain reaction. The cytopathic effect (CPE) and viral infective rate were observed by immunofluorescence microscopy.

Results: PVP-I at a concentration >0.5 mg/ml in contact with SARS-CoV-2 for 30 s, 1 min, 2 min and 5 min showed up to 99% viral inhibition. For in vitro testing, upon exposure for 1 min, PVP-I showed a virucidal effect. PVP-I had no cytotoxic effects at the range of concentrations tested (0.125-1 mg/ml; CC50 > 2.75 mM) in Vero and Calu-3 cells.

Conclusion: These results demonstrate that the ideal contact time was 1 min and the optimal concentration was 1 mg/ml, which provides an experimental basis for the use of oral disinfectants in dental hospitals.

Keywords

Povidone-iodine; SARS-CoV-2; antiviral effect; prophylaxis; public health.

Figures
Products